A Phase II Trial of Personalized Immunotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck That Have Progressed on Prior Immunotherapy
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Feb 2024 Planned End Date changed from 31 Aug 2029 to 12 Aug 2024.
- 05 Feb 2024 Planned primary completion date changed from 31 Aug 2029 to 12 Aug 2023.
- 05 Feb 2024 Status changed from recruiting to active, no longer recruiting.